Core Insights - Q32 Bio Inc. announced topline results from the SIGNAL-AA Phase 2a trial for bempikibart in alopecia areata, planning to expand the trial by enrolling additional patients [1][4] - The trial did not meet its primary endpoint in Part B, leading to a review of results and exclusion of one site from efficacy analysis due to protocol violations [2] - A post-hoc analysis indicated that bempikibart showed a 16% reduction in SALT score at week 24 compared to 2% in placebo, with 9% of patients achieving SALT-20 [3] SIGNAL-AA Trial Results - Bempikibart was safe and well-tolerated, with no serious adverse events reported [4] - The company plans to enroll approximately 20 additional patients in the Part B expansion of the SIGNAL-AA trial [4] Future Plans - Enrollment for the planned Phase 2 trial of ADX-097 in ANCA-Associated Vasculitis has been deferred to focus on ongoing trials for bempikibart and ADX-097 renal basket [5] SIGNAL-AD Trial Update - In the SIGNAL-AD trial, patients treated with bempikibart showed significant improvements in EASI scores, with 58% improvement at 2mg/kg and 84% at 3mg/kg compared to 38% in placebo [6] - Part B of the SIGNAL-AD trial showed a 74% improvement in EASI for bempikibart, compared to 76% for placebo, which was not statistically significant [7] Pharmacokinetics and Biomarkers - Bempikibart demonstrated favorable pharmacokinetics and target engagement, with substantial reductions in Th2 and Th1 biomarkers [8] Stock Performance - Q32 Bio Inc.'s stock price decreased by 67.1%, trading at $8.04 [9]
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?